|
|
|
|
|
|
|
|
|
21.08.26 - 12:51
|
The Buckle, Inc. Reports Second Quarter Net Income (Business Wire)
|
|
|
KEARNEY, Neb.--(BUSINESS WIRE)--The Buckle, Inc. (NYSE: BKE) announced today that net income for the fiscal quarter ended August 1, 2026 was $44.4 million, or $0.88 per share ($0.87 per share on a diluted basis).
Net sales for the 13-week fiscal quarter ended August 1, 2026 increased 4.6 percent to $319.8 million from net sales of $305.7 million for the prior year 13-week fiscal quarter ended August 2, 2025. Comparable store net sales for the 13-week fiscal quarter ended August 1, 2026 increased 2.1 percent from comparable store net sales for the prior year 13-week period ended August 2, 2025. Online sales increased 2.3 percent to $44.6 million for the 13-week fiscal quarter ended August 1, 2026, compared to net sales of $43.6 million for the 13-week fiscal quarter ended August 2, 2025.
Net sales for the 26-week fiscal period ended August 1, 2026 increased 5.3 percent to $608.6 million from net sales of $577.9 million for the prior year 26-week fiscal period ended August 2, 2025. Comparable store net sale...
|
|
|
|
|
21.08.26 - 01:21
|
"Get Long And Buckle Up": Jeff Currie Says Commodity Bull Market Entering Next Leg (ZeroHedge)
|
|
|
"Get Long And Buckle Up": Jeff Currie Says Commodity Bull Market Entering Next Leg
The breadth of the commodity advance is becoming increasingly difficult to ignore.
Quantix Commodity Index
Diesel crack spreads have surged above $100, copper is trading above $14,000 a ton in London, gold and silver are accelerating amid US Treasury market intervention, and the Bloomberg Agriculture Spot Index is surging higher. At the same time, the dollar weakened sharply following Treasury Secretary Scott Bessent's intervention this week, providing an additional tailwind to the commodity complex.
According to veteran commodities strategist Jeff Currie, the convergence of tight physical markets, currency debasement, and policy intervention represents the hallmark of a structural commodity bull cycle.
Currie, the former Goldman Sachs commodities chief and now co-chair of Abaxx Markets, wrote in a ten-post thread on X that commodities are the clear winners as physical bottlenecks materialize around t...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.08.26 - 15:06
|
Volvo Car USA encourages drivers to buckle up every member of the family – including four-legged ones – for Dogust (Cision)
|
|
|
This August, Volvo Car USA is reminding pet owners that the safest road trips start with every occupant properly secured – including their dogs. As part of Dogust, the annual celebration recognizing August 1 as the birthday for rescue and shelter dogs, Volvo Car USA partnered with YouGov to survey U.S. dog owners about their driving habits with their furry co-pilots.
According to the survey results, 93% of dog owners confirmed their dogs ride in their vehicles, but of those, 61% do not use safety restraints when their dog is riding in the car. In addition, 73% of dog owners whose dogs ride...
|
|
|
06.08.26 - 12:54
|
The Buckle, Inc. Reports July 2026 Net Sales (Business Wire)
|
|
|
KEARNEY, Neb.--(BUSINESS WIRE)--The Buckle, Inc. (NYSE: BKE) announced today that comparable store net sales, for stores open at least one year, for the 4-week period ended August 1, 2026 increased 1.6 percent from comparable store net sales for the 4-week period ended August 2, 2025. Net sales for the 4-week fiscal month ended August 1, 2026 increased 4.1 percent to $115.4 million from net sales of $110.8 million for the prior year 4-week fiscal month ended August 2, 2025.
Comparable store net sales for the 13-week second quarter ended August 1, 2026 increased 2.1 percent from comparable store net sales for the 13-week period ended August 2, 2025. Net sales for the 13-week fiscal second quarter ended August 1, 2026 increased 4.6 percent to $319.8 million compared to net sales of $305.7 million for the prior year 13-week fiscal second quarter ended August 2, 2025.
Comparable store net sales year-to-date for the 26-week period ended August 1, 2026 increased 3.5 percent from comparable store net sales for t...
|
|
|
|
|
29.07.26 - 20:33
|
K MED stärkt seine strategische und wissenschaftliche Führung, um die Entwicklung seiner therapeutischen Mikroimplantate voranzutreiben (Business Wire)
|
|
|
François Romaneix wird zum Vorsitzenden des Vorstands ernannt.
Prof. Philippe Leboulch tritt dem Vorstand und dem wissenschaftlichen Beirat bei.
Prof. Alain Fischer wird Vorsitzender des wissenschaftlichen Beirats.
Isabelle Buckle und Tom Tice werden in den Vorstand berufen.
PARIS & LYON, Frankreich--(BUSINESS WIRE)--PK MED, ein französisches Biotechnologieunternehmen, das von Truffle Capital (Gründer von Abivax und Carvolix) gegründet wurde und therapeutische Mikroimplantate zur Deckung großer medizinischer Bedürfnisse entwickelt, gibt heute eine erhebliche Stärkung seiner Unternehmensführung bekannt. Das Unternehmen stärkt die Struktur seines Vorstands und seines wissenschaftlichen Beirats, um den bevorstehenden Eintritt seines am weitesten fortgeschrittenen Wirkstoffkandidaten ARTHRELIS (Behandlung von Gichtanfällen) in die Phase 2 zu unterstützen und die präklinische Entwicklung von ENGRAFTIS (Behandlung einer schlechten Transplantatfunktion nach einer Knochenmarktransplantation) zu beschl...
|
|
|
29.07.26 - 09:03
|
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants (Business Wire)
|
|
|
François Romaneix is appointed Chairman of the Board of Directors.
Prof. Philippe Leboulch joins the Board of Directors and the Scientific Advisory Board.
Prof. Alain Fischer becomes Chairman of the Scientific Advisory Board.
Isabelle Buckle and Tom Tice are appointed to the Board of Directors.
PARIS & LYON, France--(BUSINESS WIRE)--PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate the preclinical development of ENGRAFTIS (treatment of poor graft function following bone marrow transplantation).
The Board of Directors of PK MED welcomes four key new members:
François Romaneix, appointed Chairman of ...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
